news

Biodesix raises additional series E financing

Posted: 13 January 2015 | Biodesix, Inc.

Biodesix, Inc., announced that the company increased the size of its offering of series E preferred shares in a follow-on sale…

Red blood, white blood and plasma cells inside an artery

Biodesix, Inc., a molecular diagnostics company that develops and commercializes blood-based tests in oncology enabling physicians to make more precise diagnostic and therapeutic decisions, announced today that the company increased the size of its offering of series E preferred shares in a follow-on sale.  In addition to the $15 million of series E shares sold in 2013 and 2014, the company brought in another $12 million, for total proceeds of $27 million from the sale.  Existing Biodesix shareholders provided nearly all of the capital.

The investment will be used for ongoing development of the company’s technology platform, new product development and expansion of commercial efforts to support Biodesix’ first product, VeriStrat®, as well as new product launches.  VeriStrat is a serum protein test that helps physicians guide therapy for patients with advanced non-small cell lung cancer (NSCLC).

“Biodesix is continuing to develop and commercialize blood-based diagnostics tests that advance precision medicine – treating the right patient at the right time with the right combination of therapies,” said David Brunel, Chief Executive Officer of Biodesix. “Securing this investment enables us to effectively bring innovative diagnostics to market that help inform treatment decisions and improve patient care in a cost effective manner.”

Biodesix and VeriStrat are registered trademarks of Biodesix, Inc.